|
¿µÇ³Á¦¾àÁÖ½Äȸ»ç |
¿µÇ³Á¦¾à °³¹ßºÎ¿¡¼ ±Ù¹«ÇÏ½Ç ½ÅÀÔ/°æ·Â ¸ðÁý
ÀÎõ ³²µ¿±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.22 |
|
|
ÁÖ½Äȸ»ç ÀνºÆÃÅͽº |
ÀǾàÇ°RA ä¿ë(½ÅÀÔ°¡´É/Á¤±ÔÁ÷)
¼¿ï ¼ºµ¿±¸ | Çз¹«°ü |
°³¹ß/RA/´ë°ü |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.30 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Oncology Pricing&Reimburse specialist¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
3³â¡è |
ä¿ë½Ã |
11.15 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Market access(Price&reimburse)specialist ¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
±¤°í/È«º¸/PR/»çº¸ |
3³â¡è |
ä¿ë½Ã |
10.29 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
RA Specialist 2¸í ä¿ë(»êÈÞ´ëü/½ÅÀÔ°¡´É)
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.14 |
|
|
¼Áö³Ê½º |
Å×ÀÌÇÁ, Á¢ÂøÁ¦, ÇÏÀ̵å·ÎÄÝ·ÎÀ̵å ÀÇ·á¿ë ÇǺΠºÀÇÕ±â(½ºÅ²
°æ±â ÀüÁö¿ª | Çз¹«°ü |
°³¹ß/RA/´ë°ü |
°æ·Â¹«°ü |
ä¿ë½Ã |
07.26 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
RA Specialist ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
1³â¡è |
ä¿ë½Ã |
06.20 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
MSDµ¿¹°¾àÇ° °ü¸®¾à»ç ¸ðÁý(½ÅÀÔ °¡´É)
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.17 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
[Çѱ¹MSD]RA Specialist ä¿ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
06.07 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Çѱ¹MSD RA Specialist Á¤±ÔÁ÷ ä¿ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
05.31 |
|
|
(ÁÖ)½Ã¹ÍÄÚ¸®¾Æ |
½Ã¹ÍÄÚ¸®¾Æ Trainer / QOL(Quality Oversight Leadership)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
5³â¡è |
ä¿ë½Ã |
02.07 |
|
|
(ÁÖ)º½¸ÞµðÄ® |
(ÁÖ)º½¸ÞµðÄ® ÀÇ·á±â±â ¹× ÀǾàÇ° ÀÎÇã°¡ RAÁ÷¿ø¸ðÁý
¼¿ï ÀüÁö¿ª, °æ±â ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
2³â¡è |
ä¿ë½Ã |
08.14 |
|
|
ÆĹ̼¿(ÁÖ) |
ÆĹ̼¿(ÁÖ) [±âȹ°³¹ßÆÀ] ¾à°¡µîÀç¾÷¹« ´ã´çÀÚ ¸ðÁý
°æ±â ¼º³²½Ã Áß¿ø±¸ | Çз¹«°ü |
°³¹ß/RA/´ë°ü |
6³â¡è |
ä¿ë½Ã |
12.13 |
|
|
(ÁÖ)½Å¾Æ¾çÇà |
¢ß½Å¾Æ¾çÇà ÀÇ·á±â±â RA ´ã´ç °æ·ÂÀÚ ¸ðÁý
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
3³â¡è |
ä¿ë½Ã |
07.24 |
|
|
¹Ì·¡Á¦¾à ÁÖ½Äȸ»ç |
¹Ì·¡Á¦¾à °³¹ßºÎ ½ÅÀÔ / °æ·ÂÁ÷ ä¿ë
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
01.06 |
|